LAVA Therapeutics Short Interest Down 69.8 percent in September
| LVTX Stock | USD 1.25 0.01 0.79% |
Slightly above 62% of LAVA Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding LAVA Therapeutics NV suggests that many traders are alarmed. LAVA Therapeutics' investing sentiment can be driven by a variety of factors including economic data, LAVA Therapeutics' earnings reports, geopolitical events, and overall market trends.
LAVA Therapeutics was the target of a significant decrease in short interest in September. As of September 30th, there was short interest totalling 9,800 shares, a decrease of 69.8 percent from the September 15th total of 32,500 shares. Based on an average daily volume of 58,300 shares, the days-to-cover ratio is
Read at thelincolnianonline.com
 |
LAVA Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards LAVA Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
LAVA Therapeutics Fundamental Analysis
We analyze LAVA Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of LAVA Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of LAVA Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
LAVA Therapeutics is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
LAVA Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with LAVA Therapeutics stock to make a market-neutral strategy. Peer analysis of LAVA Therapeutics could also be used in its relative valuation, which is a method of valuing LAVA Therapeutics by comparing valuation metrics with similar companies.
Peers
LAVA Therapeutics Related Equities
| NXTC | NextCure | 7.80 | ||||
| XLO | Xilio Development | 7.42 | ||||
| ASMB | Assembly Biosciences | 7.36 | ||||
| ACRV | Acrivon Therapeutics, | 5.45 | ||||
| DSGN | Design Therapeutics | 4.76 | ||||
| ANEB | Anebulo Pharmaceuticals | 4.08 | ||||
| PMVP | Pmv Pharmaceuticals | 3.57 | ||||
| RZLT | Rezolute | 2.29 | ||||
| ADAG | Adagene | 1.72 | ||||
| EWTX | Edgewise Therapeutics | 1.58 | ||||
| ERAS | Erasca | 1.57 | ||||
| IKNA | Ikena Oncology | 0.91 | ||||
| GBIO | Generation Bio | 0.34 | ||||
| CCCC | C4 Therapeutics | 0.72 | ||||
| TIL | Instil Bio | 1.22 | ||||
| ANTX | AN2 Therapeutics | 2.44 | ||||
| KRON | Kronos Bio | 4.23 |
Additional Tools for LAVA Stock Analysis
When running LAVA Therapeutics' price analysis, check to measure LAVA Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LAVA Therapeutics is operating at the current time. Most of LAVA Therapeutics' value examination focuses on studying past and present price action to predict the probability of LAVA Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LAVA Therapeutics' price. Additionally, you may evaluate how the addition of LAVA Therapeutics to your portfolios can decrease your overall portfolio volatility.